[go: up one dir, main page]

PE20030347A1 - Composiciones farmaceuticas, kits y procedimientos que comprenden combinaciones de agonistas/antagonistas de estrogenos, estrogenos y progestinas - Google Patents

Composiciones farmaceuticas, kits y procedimientos que comprenden combinaciones de agonistas/antagonistas de estrogenos, estrogenos y progestinas

Info

Publication number
PE20030347A1
PE20030347A1 PE2002000676A PE2002000676A PE20030347A1 PE 20030347 A1 PE20030347 A1 PE 20030347A1 PE 2002000676 A PE2002000676 A PE 2002000676A PE 2002000676 A PE2002000676 A PE 2002000676A PE 20030347 A1 PE20030347 A1 PE 20030347A1
Authority
PE
Peru
Prior art keywords
estrogen
progestines
agonists
antagonists
kits
Prior art date
Application number
PE2002000676A
Other languages
English (en)
Inventor
David Duane Thompson
Huz Zhu Ke
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20030347A1 publication Critical patent/PE20030347A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

SE REFIERE A COMPOSICIONES FARMACEUTICAS, KITS Y PROCEDIMIENTOS QUE COMPRENDEN COMBINACIONES DE AGONISTAS/ANTAGONISTAS DE ESTROGENOS, ESTROGENOS Y PROGESTINAS, SIENDO UNA COMPOSICION PREFERIDA QUE COMPRENDE EL COMPUESTO (-)-CIS-6-FENIL-5-[4-(2-PIRROLIDIN-1-ILETOXI)FENIL]-5,6,7,8-TETRAHIDRONAFTALEN-2-OL O UNA DE SUS SALES DE ADICION DE ACIDOS O EN FORMA DE LA SAL TARTRATO FARMACEUTICAMENTE ACEPTABLE Y UN ESTROGENO. SE REFIERE TAMBIEN A PROCEDIMIENTOS PARA TRATAL EL TRASTORNO DEL IMPULSO SEXUAL EN UN PACIENTE COMPRENDIENDO ADMINISTRAR UNA CANTIDAD TERAPEUTICAMENTE EFICAZ DEL COMPUESTOS MENCIONADO O UNA DE SUS SALES, UN ESTROGENO Y UNA PROGESTINA
PE2002000676A 2001-07-31 2002-07-26 Composiciones farmaceuticas, kits y procedimientos que comprenden combinaciones de agonistas/antagonistas de estrogenos, estrogenos y progestinas PE20030347A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30906501P 2001-07-31 2001-07-31

Publications (1)

Publication Number Publication Date
PE20030347A1 true PE20030347A1 (es) 2003-04-10

Family

ID=23196523

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000676A PE20030347A1 (es) 2001-07-31 2002-07-26 Composiciones farmaceuticas, kits y procedimientos que comprenden combinaciones de agonistas/antagonistas de estrogenos, estrogenos y progestinas

Country Status (14)

Country Link
US (1) US7030157B2 (es)
EP (1) EP1411922A1 (es)
JP (1) JP2005504032A (es)
KR (1) KR100567718B1 (es)
CN (1) CN1599606A (es)
CA (1) CA2448235A1 (es)
CZ (1) CZ2004118A3 (es)
HU (1) HUP0401268A2 (es)
IL (1) IL158871A0 (es)
PE (1) PE20030347A1 (es)
PL (1) PL367094A1 (es)
SK (1) SK622004A3 (es)
WO (1) WO2003011282A1 (es)
ZA (1) ZA200308809B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
IL145838A (en) * 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist/antagonist for the manufacture of a medicament for treating vaginitis
TW200307553A (en) * 2002-05-24 2003-12-16 Akzo Nobel Nv Treatment of post-menopausal complaints in breast cancer patients
MXPA05006526A (es) * 2002-12-18 2006-02-17 Besins Int Lab Tratamiento de mastalgia con 4-hidroxi tamoxifen.
JP5069469B2 (ja) * 2003-12-15 2012-11-07 ラボラトワール ブザン アンテルナスィヨナル 女性化乳房治療用の薬剤を製造する際の４−ヒドロキシタモキシフェンの使用
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
EP1550440A1 (en) * 2003-12-15 2005-07-06 Laboratoires Besins International Use of 4-hydroxytamoxifen for the preparation of a medicament for the treatment of gynecomastia
US20070166414A1 (en) * 2006-01-13 2007-07-19 Andreas Constantinou Method for enhancing tamoxifen efficacy as a cancer therapeutic
US7891492B2 (en) * 2007-08-13 2011-02-22 Carton Service, Incorporated Pharmaceutical blister card package
US20090163990A1 (en) * 2007-12-19 2009-06-25 Chunlin Yang Decellularized omentum matrix and uses thereof
WO2010099003A2 (en) * 2009-02-26 2010-09-02 Oncolix, Inc. Compositions and methods for visualizing and eliminating cancer stem cells
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150037436A1 (en) 2013-07-30 2015-02-05 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10912864B2 (en) 2015-07-24 2021-02-09 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
US11052175B2 (en) 2015-08-19 2021-07-06 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12227A (en) * 1855-01-09 Improvement in machines for forming kettles from metal disks
US128276A (en) * 1872-06-25 Improvement in sash-holders
GB8813353D0 (en) 1988-06-06 1988-07-13 Ici Plc Therapeutic product
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5591753A (en) * 1994-01-28 1997-01-07 Eli Lilly And Company Combination treatment for osteoporosis
US5552401A (en) 1995-02-28 1996-09-03 Eli Lilly And Company 2-benzyl-3-arylbenzothiophenes
US5510357A (en) 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
US6395755B1 (en) 1995-03-10 2002-05-28 Eli Lilly And Company Benzothiophene pharmaceutical compounds
ATE183516T1 (de) 1995-09-08 1999-09-15 Karobio Ab Waisen-rezeptor
UA51676C2 (uk) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US5843984A (en) 1996-05-09 1998-12-01 Eli Lilly And Company Sulfated benzothiophene derivatives, methods of use and formulations containing same
CA2217810A1 (en) * 1996-10-10 1998-04-10 Eli Lilly And Company 2-aryl-3-aminoaryloxynaphthyl compounds, intermediates, compositions and methods
JPH10204082A (ja) 1996-10-25 1998-08-04 Eli Lilly & Co 選択的エストロゲンレセプターモジュレーターとしての活性を有する置換されたベンゾ［ｂ］チオフェン化合物
WO1998040076A1 (en) 1997-03-10 1998-09-17 Schering Aktiengesellschaft Compositions for the treatment of climacteric disorders with nitric oxide synthase substrates and/or donors, in combination with partial estrogen antagonists
US6653297B1 (en) 1997-07-03 2003-11-25 Medical College Of Hampton Roads Control of selective estrogen receptor modulators
ID24568A (id) 1997-11-06 2000-07-27 American Home Prod Kontrasepsi oral yang mengandung anti-estrogen plus progestin
US5891868A (en) 1997-11-21 1999-04-06 Kaiser Foundation Health Plan, Inc. Methods for treating postmenopausal women using ultra-low doses of estrogen
WO1999039581A1 (en) 1998-02-06 1999-08-12 Huntsman Petrochemical Corporation Methomyl solvent systems
EP0950417A3 (en) * 1998-02-23 2000-02-23 Pfizer Products Inc. Treatment of skeletal disorders
US6190693B1 (en) 1998-04-17 2001-02-20 Ortho-Mcneil Pharamceutical, Inc. Pharmaceutical methods of delivering folic acid
PT1076558E (pt) 1998-05-15 2003-11-28 Wyeth Corp 2-fenil-1-¬4-(2-aminoetoxi)-benzil|-indole em combinacao com estrogenios
CA2331318A1 (en) 1998-05-15 1999-11-25 James Harrison Pickar Compositions comprising 2-phenyl-indole compounds and estrogen formulations
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
EP0966968B1 (en) 1998-06-16 2004-05-06 Pfizer Products Inc. Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin E2
GB9816897D0 (en) 1998-08-04 1998-09-30 Merck Sharp & Dohme Therapeutic use
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
AU4825200A (en) 1999-05-07 2000-11-21 Board Of Regents, The University Of Texas System Oral steroidal hormone compositions and methods of use
WO2000074684A1 (en) 1999-06-04 2000-12-14 The General Hospital Corporation Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use
AR034100A1 (es) 1999-10-15 2004-02-04 Orion Corp Uso de un compuesto estrogenico para la fabricacion de un medicamento
AR035564A1 (es) * 2000-01-28 2004-06-16 Endorech Inc Moduladores selectivos de receptores de estrogenos en combinacion con estrogenos
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
IL145838A (en) 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist/antagonist for the manufacture of a medicament for treating vaginitis

Also Published As

Publication number Publication date
CN1599606A (zh) 2005-03-23
EP1411922A1 (en) 2004-04-28
JP2005504032A (ja) 2005-02-10
HUP0401268A2 (hu) 2004-11-29
SK622004A3 (en) 2004-08-03
KR20040019095A (ko) 2004-03-04
IL158871A0 (en) 2004-05-12
WO2003011282A1 (en) 2003-02-13
CZ2004118A3 (cs) 2004-09-15
KR100567718B1 (ko) 2006-04-05
CA2448235A1 (en) 2003-02-13
US7030157B2 (en) 2006-04-18
ZA200308809B (en) 2004-11-23
US20030065017A1 (en) 2003-04-03
PL367094A1 (en) 2005-02-21

Similar Documents

Publication Publication Date Title
PE20030347A1 (es) Composiciones farmaceuticas, kits y procedimientos que comprenden combinaciones de agonistas/antagonistas de estrogenos, estrogenos y progestinas
JOP20220069A1 (ar) عوامل محللة لـ brd9 ثنائية الوظيفة وطرق لاستخدامها
ECSP066383A (es) Derivados de 5-fenil-4-metil-tiazol-2-il-amina como inhibidores de enzimas de cinasa fosfatidilinositol 3 (pi3) para el tratamiento de enfermedades inflamatorias de las vías respiratorias
PA8591701A1 (es) Derivados de pirrolopirimidina
GEP20115199B (en) Phosphatidylinositol 3-kinase inhibitors and their use
AR045972A1 (es) Formulaciones de tramadol de liberacion sostenida con eficacia de 24 horas
UY30440A1 (es) Nuevos compuestos
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
SE0200979D0 (sv) New compounds
UY26977A1 (es) Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgésicos
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
BR0214199A (pt) Composições de fenóxi amina para liberar agentes ativos, forma de unidade de dosagem e método de administração
MX2009001660A (es) Compuestos de 2,5-dihidroxibenceno para el tratamiento de psoriasis.
EA200870302A1 (ru) 1,3-диоксанкарбоновые кислоты
ECSP066950A (es) Combinaciones de glicopirrolato y agonistas del adrenoceptor-beta2
CR9721A (es) Compuestos de carbamato para utilizar en el tratamiento de desordenes neurodegenerativos
CY1109732T1 (el) Χρησις παραγωγων βενζο-συνενωμενου ετεροκυκλο σουλφαμιδιου δια την θεραπειαν πονου
AR029373A1 (es) Metodo para el tratamiento de migranas, utilizando compuestos antagonistas selectivos de los receptores iglur5, uso de dichos compuestos antagonistas selectivos en la manufactura de medicamentos para el tratamiento de migranas y dichos compuestos antagonistas
PA8542901A1 (es) Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple
CO6220902A2 (es) Formulacion en polvo del valganciclovir
PA8467401A1 (es) Procedimiento para tratar la insuficiencia cardiaca
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
UY29085A1 (es) Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
BRPI0518231A2 (pt) derivados de 2-amido-4-feniltiazol, o respectivo preparo e a respectiva aplicaÇço em terapÊutica
AR054445A1 (es) Formulaciones de un inhibidor de src/abl

Legal Events

Date Code Title Description
FC Refusal